Sida 1 från 21 resultat
This application is related to U.S. Disclosure Document No. 520,804 that has the Filing Date of Oct. 29, 2002 that is entitled "Additional Methods of Using the Inhalers for Sports Performance, to Enhance memory, To Prevent, Treat or Cure PMS, Hot Flashes, and Night Sweats, to Treat or Reduce Stress,
BACKGROUND OF THE INVENTION
One of the inventors has poor respiratory health, has had repeated bouts with pneumonia, colds, flu, asthma, and has been recently diagnosed with the initial stages of emphysema--despite all that modern medicine has had to offer. This first inventor also comes from a
TECHNICAL FIELD
The invention concerns a method for the management of cancer and treatment cancer comorbidities, including but not limited to cancer-related fatigue, cachexia, anorexia, pain, anemia, asthenia, depression, impaired cognitive function, loss of appetite, muscle weakness, nausea,
TECHNICAL FIELD
The present invention relates to NK.sub.1 receptor antagonist useful as medicaments.
More particularly, the present invention relates to NK.sub.1 receptor antagonist or pharmaceutically acceptable salts thereof which have substance P/neurokinin 1 (NK.sub.1) receptor antagonist
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention generally relates to non-effervescent, solid dosage forms adapted for oral administration of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carb- azol-4-one (ondansetron) as an anti-emetic active
TECHNICAL FIELD
The present invention relates to cyclohexyl pyridine derivatives useful as medicaments.
More particularly, the present invention relates to cyclohexyl pyridine derivatives or pharmaceutically acceptable salts thereof which have substance P/neurokinin 1 (NK.sub.1) receptor antagonist
TECHNICAL FIELD
The present invention relates to cyclohexyl pyridine derivatives useful as medicaments.
More particularly, the present invention relates to cyclohexyl pyridine derivatives or pharmaceutically acceptable salts thereof which have substance P/neurokinin 1 (NK.sub.1) receptor antagonist
BACKGROUND
Cannabinoid receptors, CB1 and CB2, are part of the endocannabinoid system (ECS), which consists of cannabinoid receptors, endogenous endocannabinoids anandamide (AEA) and 2-arachindonoylglycerol (2-AG) and the hydrolytic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol
BACKGROUND OF THE INVENTION
1. Technical Field of the Invention
The present invention generally relates to a multi-parameter physiological conditioning method and apparatus, and particularly to an autogenic-feedback training exercise method for training people to gain better control of specific
BACKGROUND OF THE INVENTION
This invention relates to tricyclic compounds. These compounds have selective acid pump inhibitory activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the treatment of disease
FIELD OF THE INVENTION
The present invention relates to novel conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds possess appropriate pharmacological
FIELD OF THE INVENTION
The invention is directed to sublingual spray formulations containing ondansetron or a pharmaceutically acceptable salt thereof. The invention is further directed to method for treating or preventing nausea and emesis associated with cancer treatments by administering
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
TECHNICAL FIELD
The present invention relates to medicinally useful preparations derived from mistletoe, methods for making such preparations and treatment methods employing such preparations. More specifically, the invention relates to an orally ingestible preparation of mistletoe lectins useful in